Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Depreciation & Amortization (CF) (2020 - 2025)

Bioventus' Depreciation & Amortization (CF) history spans 6 years, with the latest figure at $11.7 million for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) fell 5.73% year-over-year to $11.7 million; the TTM value through Dec 2025 reached $47.0 million, down 5.13%, while the annual FY2025 figure was $47.0 million, 5.13% down from the prior year.
  • Depreciation & Amortization (CF) reached $11.7 million in Q4 2025 per BVS's latest filing, up from $11.4 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $16.9 million in Q4 2022 to a low of $7.2 million in Q2 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $12.2 million, with a median of $12.3 million recorded in 2022.
  • Peak YoY movement for Depreciation & Amortization (CF): skyrocketed 73.71% in 2022, then decreased 28.46% in 2024.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $11.7 million in 2021, then surged by 44.93% to $16.9 million in 2022, then fell by 26.43% to $12.5 million in 2023, then dropped by 0.48% to $12.4 million in 2024, then dropped by 5.73% to $11.7 million in 2025.
  • Per Business Quant, the three most recent readings for BVS's Depreciation & Amortization (CF) are $11.7 million (Q4 2025), $11.4 million (Q3 2025), and $12.0 million (Q2 2025).